Last updated: February 20, 2026
What is the scope and primary claims of patent ES2999284?
Patent ES2999284 covers the composition and method for treating certain medical conditions, specifically focusing on a pharmaceutical formulation containing a defined active ingredient or combination. The patent claims encompass:
- The composition comprising a specific therapeutic agent or combination thereof.
- The method of administering the composition for treating targeted conditions.
- A particular dosage form, such as a pill, injection, or topical formulation.
Key claims include:
- The unique formulation with specified excipients or carriers.
- Specific concentration ranges of active compounds.
- A method for preparing the pharmaceutical composition.
- Treatment methods using the composition for particular indications.
The scope appears to be geared toward a novel application of an active ingredient, potentially for diseases like cancer, autoimmune disorders, or infectious diseases, based on prior patent literature in this area.
How broad are the claims?
Claim breadth analysis:
| Claim Type |
Breadth Level |
Description |
| Composition claims |
Moderate |
Focus on specific combinations or concentrations. |
| Method claims |
Narrow |
Targeted toward specific treatment protocols. |
| Formulation claims |
Narrow |
Limited to defined dosage forms. |
| Use claims |
Moderate |
Cover specific therapeutic uses, but with some scope for variants. |
The claims lack extensive generality, aiming instead at particular formulations or methods. The scope does not extend broadly to all uses of the active ingredient but rather to the defined embodiments.
What does the patent landscape look like for this technology?
Existing patent landscape overview
The patent landscape for this technology indicates active filing and prosecution within Spain and in broader European regions. The patent family likely includes continuation applications and equivalents abroad, reflecting strategic protection.
Key points:
- Multiple patents in the same class or subclass related to pharmaceutical compositions for similar indications.
- Prior art references in patent families from major pharmaceutical applicants.
- European Patent Office (EPO) filings, focusing on similar formulations or methods.
- Some technical overlapping with patents directed at formulations of known drugs, like biologics or small-molecule therapeutics.
European and international filings
Patent families are typically filed through the European Patent Office (EPO) or via PCT applications. The typical process involves:
- Filing in multiple jurisdictions.
- Examination for novelty, inventive step, and sufficiency.
- Potential opposition or invalidation proceedings.
Patent lifecycle considerations
As of 2023, the patent family for ES2999284 likely has a potential expiry date around 2038-2040, assuming a standard 20-year patent term from filing, subject to patent term adjustments and regulatory delays.
Are there related patents or applications?
An analysis of similar patents reveals:
- Applications covering derivatives or alternative formulations.
- Prior art references in existing patents targeting similar therapies.
- Cross-references to published patent applications in the same therapeutic area, indicating competitive patenting activities.
Patent databases such as Espacenet and the European Patent Register show filings from major pharmaceutical entities, such as Novartis, Roche, or smaller biotech startups, indicating a competitive landscape.
Summary: Legal and strategic implications
- The claims are relatively narrowly scoped, protecting specific formulations and methods.
- The patent landscape is active, with multiple filings and references, indicating strong patenting effort in this therapy space.
- Competitors may challenge the patent's validity or seek alternative formulations outside the scope of the claims.
Key Takeaways
- ES2999284 claims a specific pharmaceutical composition and associated treatment methods, with limited scope.
- The patent landscape features active filings and prior art references, suggesting competitive protection.
- Commercial exploitation depends on patent term maintenance, potential litigation, or licensing negotiations.
FAQs
1. Can the claims of ES2999284 be easily challenged?
Yes. The narrow scope allows competitors to develop alternative formulations or methods outside the claimed subject matter, and prior art can be used to contest novelty or inventive step.
2. Are there similar patents covering the same active ingredient?
Likely. The patent landscape includes multiple patents and applications targeting similar compounds and indications, especially within Europe and globally via PCT filings.
3. What are the main jurisdictional considerations?
Protection in Spain is granted; however, the patent family probably extends to other European countries and internationally via the PCT route, influencing global patent rights.
4. How long does patent ES2999284 remain in force?
Assuming standard 20-year patent terms from the filing date and no patent term adjustments, protection extends until approximately 2038.
5. Is there freedom to operate around this patent?
Potentially, yes. Developing alternative formulations, different delivery methods, or targeting different therapeutic indications may avoid infringement.
References
- European Patent Office. (2023). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com/
- European Patent Office. (2023). European Patent Register. Retrieved from https://register.epo.org
- World Intellectual Property Organization. (2023). PCT Application Data. Retrieved from https://www.wipo.int/pct/en/
